公开(公告)号：US5110808A

公开(公告)日：1992-05-05

申请号：US738436

申请日：1991-07-31

申请人： David R. Brittain ,  Steven P. Brown ,  Anthony L. Cooper ,  Jethro L. Longridge ,  Jeffrey J. Morris ,  John Preston ,  Linda Slater

发明人： David R. Brittain ,  Steven P. Brown ,  Anthony L. Cooper ,  Jethro L. Longridge ,  Jeffrey J. Morris ,  John Preston ,  Linda Slater

IPC分类号： A61K31/255 ,  A61P3/08 ,  A61P3/10 ,  A61P43/00 ,  C07C317/40 ,  C07C317/42 ,  C07D295/14 ,  C07D295/185

CPC分类号： C07D295/185 ,  C07C317/40 ,  C07C317/42

摘要： The invention concerns novel (oxamido- and ureido-phenylsulfonyl)nitromethane derivatives and pharmaceutically acceptable salts thereof which are inhibitors of the enzyme aldose reductase and are of value, for example, in the treatment of certain peripheral effects of diabetes and galactosemia. Also disclosed are pharmaceutical compositions containing one of the derivatives and processes for the manufacture and use of the derivatives.

公开(公告)号：US5430060A

公开(公告)日：1995-07-04

申请号：US120760

申请日：1993-09-15

申请人： David R. Brittain ,  Steven P. Brown ,  Anthony L. Cooper ,  Jethro L. Longridge ,  Jeffrey J. Morris ,  John Preston ,  Linda Slater

发明人： David R. Brittain ,  Steven P. Brown ,  Anthony L. Cooper ,  Jethro L. Longridge ,  Jeffrey J. Morris ,  John Preston ,  Linda Slater

IPC分类号： A61K31/255 ,  A61K31/00 ,  A61K31/04 ,  A61K31/10 ,  A61K31/16 ,  A61P3/00 ,  A61P3/08 ,  A61P3/10 ,  A61P5/00 ,  A61P25/02 ,  A61P27/00 ,  A61P43/00 ,  C07C313/04 ,  C07C315/00 ,  C07C315/02 ,  C07C317/14 ,  C07C317/40 ,  C07C323/41 ,  A61K31/165 ,  C07C233/57

CPC分类号： C07C317/40 ,  C07C313/04 ,  C07C323/41 ,  C07C2101/02 ,  C07C2101/04 ,  C07C2101/08 ,  C07C2102/06 ,  C07C2102/08 ,  Y10S514/866

摘要： The invention concerns novel N-phenylacetyl and related acyl derivatives of (4-amino-2,6-dimethylphenylsulphonyl)nitromethane and pharmaceutically acceptable salts thereof which are inhibitors of the enzyme aldose reductase and are of value, for example, in the treatment of certain peripheral effects of diabetes and galactosemia. Also disclosed are pharmaceutical compositions containing one of the derivatives and processes for the manufacture and use of the derivatives.

摘要翻译： 本发明涉及（4-氨基-2,6-二甲基苯磺酰基）硝基甲烷的新型N-苯基乙酰基和相关酰基衍生物及其药学上可接受的盐，其是酶醛糖还原酶的抑制剂，并且具有例如某些 糖尿病和半乳糖血症的外周作用。 还公开了含有制备和使用衍生物的衍生物和方法之一的药物组合物。

公开(公告)号：US5250570A

公开(公告)日：1993-10-05

申请号：US999690

申请日：1992-12-31

申请人： David R. Brittain ,  Steven P. Brown ,  Anthony L. Cooper ,  Jethro L. Longridge ,  Jeffrey J. Morris ,  John Preston ,  Linda Slater

发明人： David R. Brittain ,  Steven P. Brown ,  Anthony L. Cooper ,  Jethro L. Longridge ,  Jeffrey J. Morris ,  John Preston ,  Linda Slater

IPC分类号： C07C313/04 ,  C07C317/40 ,  C07C323/41 ,  C07C323/60 ,  A61K31/165

CPC分类号： C07C317/40 ,  C07C313/04 ,  C07C323/41 ,  C07C323/60 ,  Y10S514/866

摘要： The invention concerns novel phenoxy- and phenylthio-acetyl derivatives of (4-amino-2,6-dimethylphenylsulphonyl)nitromethane and pharmaceutically acceptable salts thereof which are inhibitors of the enzyme aldose reductase and are of value, for example, in the treatment of certain peripheral effects of diabetes and galactosemia. Also disclosed are pharmaceutical compositions containing one of the derivatives and processes for the manufacture and use of the derivatives.

摘要翻译： 本发明涉及（4-氨基-2,6-二甲基苯基磺酰基）硝基甲烷的新型苯氧基 - 和苯硫基 - 乙酰基衍生物及其药学上可接受的盐，其是酶醛糖还原酶的抑制剂，并且具有例如某些 糖尿病和半乳糖血症的外周作用。 还公开了含有制备和使用衍生物的衍生物和方法之一的药物组合物。

公开(公告)号：US5189031A

公开(公告)日：1993-02-23

申请号：US831434

申请日：1992-01-05

申请人： David R. Brittain ,  Steven P. Brown ,  Anthony L. Cooper ,  Jethro L. Longridge ,  Jeffrey J. Morris ,  John Preston ,  Linda Slater

发明人： David R. Brittain ,  Steven P. Brown ,  Anthony L. Cooper ,  Jethro L. Longridge ,  Jeffrey J. Morris ,  John Preston ,  Linda Slater

IPC分类号： A61K31/255 ,  A61P3/08 ,  A61P3/10 ,  A61P43/00 ,  C07C317/40 ,  C07C317/42 ,  C07D295/14 ,  C07D295/185

CPC分类号： C07D295/185 ,  C07C317/40 ,  C07C317/42

摘要： The invention concerns novel (oxamido- and ureido-phenylsulfonyl)nitromethane derivatives and pharmaceutically acceptable salts thereof which are inhibitors of the enzyme aldose reductase and are of value, for example, in the treatment of certain peripheral effects of diabetes and galactosemia. Also disclosed are pharmaceutical compositions containing one of the derivatives and processes for the manufacture and use of the derivatives.